6/30/2010 | DD | Oscient emerges from bankruptcy as liquidation plan takes effect
|
6/29/2010 | DD | Oscient Pharmaceuticals: bankruptcy court confirms liquidation plan
|
5/27/2010 | DD | Oscient disclosure statement approved; plan hearing set for June 29
|
3/26/2010 | DD | Oscient seeks conversion of Chapter 11 bankruptcy case to Chapter 7
|
3/11/2010 | DD | Oscient gets brief exclusivity extension, must fight case conversion
|
2/12/2010 | DD | Oscient Pharmaceuticals' official committee opposes exclusivity
|
2/11/2010 | DD | Oscient files liquidation plan, eyes extension to win creditor support
|
1/25/2010 | DD | Oscient Pharmaceuticals secures 15-day exclusivity extension
|
1/22/2010 | DD | Oscient Pharmaceuticals asks court for 15-day exclusivity extension
|
12/11/2009 | DD | Oscient Pharmaceuticals granted one-month exclusivity extension
|
12/10/2009 | DD | Oscient eyes one-month exclusivity extension to resolve sale issues
|
11/10/2009 | DD | Oscient Pharmaceuticals granted 30-day exclusivity extension
|
11/9/2009 | DD | Oscient requests 30-day exclusivity extension to resolve issues
|
9/22/2009 | DD | Oscient Pharmaceuticals sells Antara drug assets for $38.61 million
|
9/4/2009 | DD | Oscient gets court OK to sell Factive for $5 million plus royalties
|
8/27/2009 | DD | Oscient receives no counteroffers for Factive; asks to cancel auction
|
8/7/2009 | DD | Oscient looks to sell high cholesterol drug Antara for $20 million
|
7/20/2009 | DD | Oscient Pharmaceuticals unsecured creditors committee appointed
|
7/13/2009 | CVDD | Oscient Pharmaceuticals files bankruptcy, to sell antibiotic assets
|
5/15/2009 | CVDDSS | Oscient updates warning about lack of cash beyond the third quarter
|
5/1/2009 | CVDD | Oscient to issue $7.44 million 12.5% convertibles due 2011 in exchange for 5% convertibles
|
4/29/2009 | CVPP | Oscient holders swap some 5% convertibles due 2009 for 12.5% convertibles due 2011
|
3/26/2009 | CVDDSS | Oscient's cash may fail to support operations beyond third quarter
|
3/25/2009 | CVDDPPSS | Oscient Pharmaceuticals looks to raise capital, explores strategic options to prevent bankruptcy
|
1/29/2009 | PP | Oscient extends maturity date of $13 million 5% convertible promissory notes
|
1/29/2009 | PP | Market Commentary: Omniture in new alliance; Oscient extends convertibles; Non-Invasive sells preferreds; Robex upsizes deal
|
11/24/2008 | CV | Oscient holders tender $213 million 3.5% convertibles in exchange offer
|
11/20/2008 | CV | Oscient Pharmaceuticals sets consideration to be issued in exchange offer for 3.5% convertibles
|
11/7/2008 | CV | Oscient Pharmaceuticals amends, extends exchange offer for 3.5% convertibles
|
10/21/2008 | CV | Oscient Pharmaceuticals starts exchange offer for 3.5% convertibles
|
9/11/2008 | CV | Market Commentary: Financial rout broadens, but Bank of America holds up; Oscient Pharma weakens after exchange news
|
9/10/2008 | CV | Oscient Pharmaceuticals plans exchange offer for 3.5% convertibles
|
4/26/2007 | CV | Oscient Pharmaceuticals gets tenders for 99% of 3.5% notes, 41% of 5% notes in exchange offer
|
4/25/2007 | CV | New Issue: Oscient sells upsized $60 million five-year 3.5% convertibles at 77.5, yields 10.7%, up 110.9%
|
4/25/2007 | CV | Market Commentary: Advanced Medical gains, RF Micro drops on earnings; Charming Shoppes up on debut; Oscient prices deal
|
4/18/2007 | CV | Oscient Pharmaceuticals increases new 3.5% convertibles offering
|
4/11/2007 | SS | Market Commentary: Manor Care spikes; Giant gains, Western Refining falls; Clear Channel steady; Take-Two rises
|
3/29/2007 | CV | Oscient Pharmaceuticals begins exchange offer for 3.5% convertibles, 5% promissory notes
|
3/15/2007 | CV | Oscient Pharmaceuticals plans exchange offer for 3.5% convertibles, 5% convertible promissory notes
|
2/23/2007 | CV | Reaping lessons from Wild Oats: Market value-based make-whole feature caps protection, says Lehman
|
11/27/2006 | SS | Ford shares, preferreds skid; Nasdaq, LSE slip; biotechs lower; Raytheon drops; Ventas falls
|
11/16/2006 | BT | Oscient focused on finding third marketed product to add to portfolio
|
11/16/2006 | BT | JMP ups Oscient price target to $18, rates at strong buy
|
11/10/2006 | BT | JMP keeps Oscient at strong buy
|
11/9/2006 | BT | Oscient's third-quarter revenues double from prior-year period to $12.4 million
|
10/11/2006 | BT | Oscient reports cash, investments of $51 million at end of third quarter
|
10/11/2006 | BT | Market Commentary: Genentech slides, Xoma adds 8%; Genzyme eases; NitroMed sinks; Oscient gains; Northfield loses 3%
|
9/26/2006 | BTCV | Oscient Pharmaceuticals files $100 million shelf registration
|
9/22/2006 | BT | Oscient gets FDA approvable letter for Factive five-day pneumonia tablets
|
9/22/2006 | BT | Oscient reiterated at strong buy by Merrill
|
9/22/2006 | BT | Market Commentary: Amgen leads sector lower; Dyax gains on Kos' loss; Oscient rises; Gene Logic up; Discovery Labs off
|
9/13/2006 | BT | Oscient: FDA advisory panel votes against Factive to treat sinusitis
|
9/13/2006 | BT | JMP keeps Oscient at strong buy
|
9/13/2006 | BT | Market Commentary: Vasogen zooms 24% on Celacade data; Cardiome off 11%; Oscient falls 11%, but fans buy on decline
|
9/12/2006 | BT | Market Commentary: Oscient may bounce on expected FDA rejection; New River rises 6%; Adolor flat, Progenics lower
|
9/8/2006 | BT | Market Commentary: Discovery Labs spikes on buyout buzz; Cell Genesys loses 5% on bought deal; Oscient buffeted
|
9/6/2006 | BT | Oscient to discuss Factive label expansion with FDA next week
|
9/5/2006 | BT | Auxilium to lease manufacturing facility, expand sales territory for Testim without Oscient
|
9/5/2006 | BT | JMP reiterated Oscient at strong buy
|
8/22/2006 | CV | Market Commentary: Mills higher on project financing deal; Developers REIT offer draws poor reviews; Scottish Re widens
|
8/21/2006 | BTPP | New Issue: Oscient wraps $10 million stock deal; subsidiary sells $20 million notes
|
8/21/2006 | BT | Market Commentary: Dynavax says flu vaccine effective on divergent viral strains; Inverness to wrap $151.25 million PIPE
|
8/21/2006 | PP | Market Commentary: Inverness secures $151.25 million from stock offering; Oscient, unit completes private placements
|
8/10/2006 | BT | Oscient Pharmaceuticals grants Factive commercialization rights to Abbott affiliate
|
8/10/2006 | BT | Market Commentary: ImClone slammed after it ditches deal search; Oscient rises 12.5%; Vical sinks
|
8/8/2006 | BT | Oscient's first-half revenue hits $15.5 million at June 30 on increased Factive sales
|
8/8/2006 | BT | Oscient reiterated at strong buy by JMP
|
7/27/2006 | BT | Market Commentary: Adams hit 4%; Conor slips after follow-on; Diomed pockets $10 million from PIPE; Oscient gains
|
7/25/2006 | BT | JMP upgrades Oscient to strong buy
|
7/24/2006 | BT | Oscient to acquire Antara capsules from Reliant for $78 million
|
7/24/2006 | BT | Market Commentary: Genitope falls 12%; Micromet off; Oscient up; DepoMed dives; Atricure off; Discovery Labs rises 10%
|
6/28/2006 | BT | Oscient: FDA to review Factive sinusitis treatment
|
6/12/2006 | BT | Oscient reiterated at market outperform by JMP
|
6/5/2006 | BT | JMP reiterates Oscient at market outperform
|
5/30/2006 | BT | JMP reiterates Oscient at market outperform
|
5/22/2006 | BT | Oscient reiterated at market outperform by JMP
|
5/19/2006 | BT | Market Commentary: Illumina gains after spot sale; Neurocrine, DOV mixed; Pozen pounded; Alkermes dips, settles higher
|
5/15/2006 | BT | Oscient reiterated at market outperform by JMP
|
5/9/2006 | BT | Oscient kept at market outperform by JMP
|
5/8/2006 | BT | JMP reiterates Oscient at market outperform
|
5/1/2006 | BT | JMP reiterates Oscient at market outperform
|
4/24/2006 | BT | Oscient reiterated at market outperform
|
4/11/2006 | BTPP | New Issue: Oscient Pharmaceuticals settles PIPE for $35.9 million
|
4/10/2006 | CV | Market Commentary: Red Hat gains 8 points outright on acquisition; Oscient keeps sliding; Rentech deal sees poor interest
|
4/7/2006 | PP | Market Commentary: Acusphere set to wrap $40.2 million direct deal; Environmental Tectonics secures $15 million equity line
|
4/6/2006 | BT | Market Commentary: Amgen a drag on biotech sector; Medarex follow-on seen on deck; Oscient up on PIPE after-hours
|
4/6/2006 | PP | Market Commentary: Oscient Pharmaceuticals gears up to wrap $34.74 million PIPE; Aastrom secures $25.51 million
|
4/6/2006 | BTPP | New Issue: Oscient Pharmaceuticals set to close $34.74 million stock sale
|
4/4/2006 | BT | Oscient's Factive tablets subject of presentations at European conference
|
3/20/2006 | BT | JMP reiterates Oscient at market outperform
|
3/6/2006 | BT | JMP keeps Oscient at market outperform
|
2/27/2006 | BT | Oscient at market outperform by JMP
|
2/21/2006 | BT | JMP keeps Oscient at market outperform
|
2/8/2006 | BT | Oscient acquires worldwide rights to Ramoplanin
|
2/8/2006 | BT | Oscient kept at market outperform by JMP
|
2/8/2006 | BT | Market Commentary: Pfizer news sparks buyout buzz; Immtech falls; Alkermes up; Icos off; Alexion higher; Oscient down
|
2/7/2006 | BT | JMP reiterates Oscient at market outperform
|
2/7/2006 | BT | Market Commentary: Alexion hits new high; Vertex up on data, earnings; Genitope lifted after deal; Oscient up on new pact
|
2/7/2006 | BT | Oscient, Pfizer enter agreement for Factive tablets in Mexico
|
2/6/2006 | BT | JMP reiterates Oscient at market outperform
|
1/30/2006 | BT | JMP reiterates Oscient at market outperform
|
1/23/2006 | BT | Oscient reiterated by JMP
|
1/20/2006 | BT | Oscient seeks FDA OK for Factive to treat pneumonia, FDA refuses sinusitis application
|
1/20/2006 | BT | JMP reiterates Oscient at market outperform
|
1/20/2006 | BT | Market Commentary: DOR BioPharma stock jumps 15.6% on orBec news, equity line; Shire, Impax settle patent suit
|
1/20/2006 | CV | Market Commentary: Hutchinson hovers around par; Schlumberger surges; Ford sags, Oscient tumbles
|
1/18/2006 | BT | Oscient reiterated by JMP at market outperform
|
1/9/2006 | BT | Market Commentary: Human Genome, Amgen higher on license pact; Alnylam soars on 2006 view; NPS, Oscient up big
|
1/3/2006 | BT | JMP reiterates Oscient at market outperform
|
12/21/2005 | BT | Oscient, FDA agree on design of phase 3 studies of Ramoplanin to treat clostridium difficile-associated disease
|
12/19/2005 | BT | Oscient says research shows Ramoplanin "highly active" against C. difficile
|
12/19/2005 | BT | Oscient reiterated by JMP at market outperform
|
12/12/2005 | BT | JMP reiterates Oscient at market outperform
|
12/5/2005 | BT | JMP reiterates Oscient's market outperform
|
11/28/2005 | BT | JMP reiterates market outperform for Oscient
|
11/21/2005 | BT | Oscient Pharmaceuticals submits FDA application for new indications for Factive
|
11/21/2005 | BT | JMP reiterates Oscient at market outperform
|
11/14/2005 | BT | JMP maintains Oscient at market outperform
|
11/2/2005 | BT | JMP reiterates Oscient outperform rating
|
10/31/2005 | BT | JMP reiterates Oscient market outperform rating
|
10/24/2005 | BT | JMP maintains Oscient at market outperform
|
10/17/2005 | BT | Oscient Pharma rated as outperform by JMP
|
10/10/2005 | BT | Oscient reiterated at market outperform by JMP
|
10/6/2005 | BT | JMP downgrades Oscient, lowers price target to $3
|
10/6/2005 | BT | Market Commentary: Endo, Panacos mixed after deals; Invitrogen off; Oscient plunges; Human Genome continues spiral
|
9/30/2005 | BT | Oscient Pharmaceuticals files $100 million shelf
|
9/19/2005 | BT | Oscient reiterated by JMP at buy
|
9/12/2005 | BT | Oscient reiterated at strong buy by JMP
|
9/6/2005 | BT | Oscient Pharma kept by JMP at strong buy
|
8/31/2005 | BT | Market Commentary: MedImmune shoots up over 10%; Chiron little changed; Glaxo gains on U.S. flu shot OK; Oscient flat
|
8/31/2005 | BT | Oscient initiated by Thomas Weisel at outperform
|
8/30/2005 | BT | Oscient reiterated by JMP at strong buy
|
8/25/2005 | BT | Market Commentary: Nastech rises in face of follow-on deal; Amylin up on takeover buzz; Antigenics convertible finds buyers
|
8/24/2005 | BT | Market Commentary: Shire rises on Adderall news; New River retraces gain; Barr declines; Genaera gains; Oscient Pharma off
|
8/23/2005 | PP | Market Commentary: ROO leads lighter U.S. PIPE volume with $5.75 million offering; iMedia raises $4.92 million
|
8/23/2005 | BT | Market Commentary: Amylin stock, convertibles zoom on drug data; OSI rebounds; Merck credit finds buyers; Wyeth sold off
|
8/15/2005 | BT | Biotechnology's solid second quarter a harbinger, Anadys one to watch, JMP Securities report says
|
8/15/2005 | BT | Oscient reiterated by JMP at strong buy
|
8/9/2005 | BT | Oscient reiterated by JMP at strong buy
|
8/2/2005 | BT | Oscient maintained by JMP at strong buy
|
7/21/2005 | BT | Market Commentary: Adams IPO zooms; Accentia stalls, again; Guilford up on MGI Pharma merger; Momenta on tap; Isis rises
|
7/14/2005 | BT | Market Commentary: Genentech active; CryoCor IPO trades up, sinks; Mylan prices tight, center; BioMarin off on follow-on
|
6/21/2004 | CV | Market Commentary: LabOne, Priceline deals emerge; Postbank sets €1 billion deal; Simon to distribute $900 million convert
|
6/8/2004 | CV | Market Commentary: Players taking a reality check in wake of Mandalay upset find the market discounted considerably
|
5/25/2004 | CV | Oscient greenshoe exercised, raising convertibles to $143.75 million
|
5/5/2004 | CV | New Issue: Oscient upsized $125 million convertible yields 3.5%, up 35%
|
5/5/2004 | CV | Market Commentary: Oscient Pharmaceuticals hits par 1/8 bid on first day of trading
|
5/4/2004 | CV | Market Commentary: ImClone trades off gray levels; five new deals surface after Fed leaves rates alone
|
5/3/2004 | CV | Oscient Pharma $75 million convertible talked at 3.5%-4.0%, up 30%-35%
|
5/3/2004 | CV | Market Commentary: ImClone bid at 102.75 even after terms tightened; Oscient emerges; Albertson's at bat; Conseco Thursday
|